On October 26, 2021, Mozart Therapeutics, Inc. closed the transaction. The company received $55 million in a round of funding co-led by new investor Sofinnova Partners SAS and returning investor Arch Venture Partners, L.P. The transaction also included participation from Altitude Life Science Ventures, Eli Lilly and Company, MRL Ventures Fund, a fund managed by M Ventures, Leaps by Bayer, Alexandria Venture Investments, LLC. As part of the transaction Steven Gillis from Arch Venture Partners, L.P., Peter Dudek from M Ventures, Julie Gilmore from Eli Lilly and Company, Lucio Iannone from Leaps by Bayer, Henrijette Richter from Sofinnova Partners SAS and Tom Danie as MD.